Patents Examined by S. Devi
  • Stable formulations of rLP2086 antigens
    Patent number: 9556240
    Abstract: The present invention relates to stable formulations of Neisseria meningitis rLP2086 Subfamily B Antigens in immunogenic compositions. The present invention also relates to methods of preserving the conformation of Neisseria meningitis rLP2086 Antigens and methods for determining the potency of Neisseria meningitis rLP2086 antigens.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: January 31, 2017
    Assignee: Wyeth LLC
    Inventors: Lakshmi Khandke, Rasappa Arumugham, Bounthon Loun
  • Recombinant bacterium and uses thereof
    Patent number: 9539313
    Abstract: The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumor antigen. Methods of imparting immunity using the recombinant bacterium are also provided.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: January 10, 2017
    Assignee: National Research Council of Canada
    Inventors: Subash Sad, Lakshmi Krishnan, Fanny Tzelepis, Valeria Alcon, Kevin G. Young
  • Vaccines against pregnancy-associated malaria
    Patent number: 9540425
    Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 10, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DéVELOPPEMENT (IRD)
    Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Sedami Ursula Alix Carine Gnidéhou, Mickaël Quiviger, Pascal Bigey, Daniel Scherman
  • Method for diagnosing bacterial infections
    Patent number: 9528997
    Abstract: The invention concerns an in vitro method for determining if an individual is infected by a bacterium of the Propionibacterium genus comprising: (i) detecting antibodies directed against at least one protein of sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, in a biological sample of the individual, and (ii) deducing therefrom that the individual is infected by a bacterium of the Propionibacterium genus. The invention further concerns the kit for diagnosing of such an infection.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: December 27, 2016
    Assignee: Diaxonhit
    Inventors: Julie Rogé, Hélène Nuyttens, Karine Mignon Godefroy, Damien Thomas, Virginie Pinchot
  • Influenza vaccine, composition, and methods of use
    Patent number: 9526778
    Abstract: The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: December 27, 2016
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale, National University of Singapore
    Inventors: Sylvie Alonso, Rui Li, Vincent Chow, Camille Locht
  • Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
    Patent number: 9511131
    Abstract: Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: December 6, 2016
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Peter Beernink, Jo Anne Welsch
  • Composition comprising probiotic bacteria for use in the treatment of immune disorders
    Patent number: 9498503
    Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: November 22, 2016
    Assignee: Probiotical S.p.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna, Lorenzo Drago
  • Combined meningococcal conjugates with common carrier protein
    Patent number: 9492558
    Abstract: Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimizes the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunizing a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 ?g/ml.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: November 15, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Paolo Costantino
  • Conjugated Vi saccharides
    Patent number: 9475846
    Abstract: Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM197 (a non-toxic variant of diphtheria toxin) and tetanus toxoid, as carrier proteins.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: October 25, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Francesca Micoli, Francesco Berti, Paolo Costantino
  • Methods, compositions and vaccines relating to antibodies
    Patent number: 9475864
    Abstract: The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against Neisseria meningitidis. The invention also provides kits for carrying out these screens, and improved vaccines against Neisseria meningitidis.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: October 25, 2016
    Assignee: University of Massachusetts
    Inventors: Sanjay Ram, Tathagat Duttaray, Peter A. Rice, Lisa A. Lewis, Sunita Gulati
  • lipopolysaccharide outer core epitope
    Patent number: 9475863
    Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula I: wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 25, 2016
    Assignee: National Research Council of Canada
    Inventors: Eleonora Altman, Blair A. Harrison, Vandana Chandan
  • Meningococcal fHBP polypeptides
    Patent number: 9468673
    Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: October 18, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
  • Conjugate purification
    Patent number: 9463250
    Abstract: This application relates to methods for the purification of saccharide antigen-carrier protein conjugates. In particular, the invention provides a method for purifying saccharide antigen-carrier protein conjugates from free carrier protein, such as CRM1 97, using hydroxyapatite. The invention further relates to methods of preparing vaccines, using this method.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: October 11, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Massimo Bigio, Giovanni Averani, Francesco Norelli, Francesco Berti, Cinzia Bellucci
  • Compositions produced using enteric pathogens and methods of use
    Patent number: 9463230
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 11, 2016
    Assignee: EPITOPIX LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Flagellin related polypeptides and uses thereof
    Patent number: 9457061
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 4, 2016
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Immunogenic proteins and compositions
    Patent number: 9458229
    Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: October 4, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guido Grandi, Domenico Maione, Cira Daniela Rinaudo
  • GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by
    Patent number: 9452208
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: September 27, 2016
    Assignee: CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Factor H binding proteins (FHBP) with altered properties and methods of use thereof
    Patent number: 9439957
    Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: September 13, 2016
    Assignee: CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND
    Inventors: Peter T. Beernink, Dan M. Granoff, Rolando Pajon Feyt
  • Conjugated ?-1,3-linked glucans
    Patent number: 9439955
    Abstract: Glucans having exclusively or mainly ?-1,3 linkages are used as immunogens. These comprise ?-1,3-linked glucose residues. Optionally, they may include ?-1,6-linked glucose residues, provided that the ratio of ?-1,3-linked residues to ?-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by ?-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolyzed to a suitable form prior to conjugation.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: September 13, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Conjugated beta-1,3-linked glucans
    Patent number: 9439954
    Abstract: Glucans having exclusively or mainly ?-1,3 linkages are used as immunogens. These comprise ?-1,3-linked glucose residues. Optionally, they may include ?-1,6-linked glucose residues, provided that the ratio of ?-1,3-linked residues to ?-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by ?-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolyzed to a suitable form prior to conjugation.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: September 13, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano